Overview
- 3 inspections across 3 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2019-05-02.
At a glance
Inspections
3
Sites
3
Observations
1
Career since
Dec 2017
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Tanvex BioPharma USA, Inc | 2 May 2019 | Human Drugs | On file |
| Samsung Bioepis Co., Ltd. | 14 Nov 2018 | Human Drugs | |
| Lonza AG | 15 Dec 2017 | Human Drugs | On file |
Sites inspected
Tanvex BioPharma USA, IncSan Diego, United States1 insp.
Samsung Bioepis Co., Ltd.Yeonsu, Korea (the Republic of)1 insp.
Lonza AGVisp, Switzerland1 insp.
Co-investigators
Investigators who share inspections with this person.
Lindsey J Brown1 shared
Thuy T Nguyen1 shared
Amanda L Fyles1 shared
Diane L Raccasi1 shared
Tracy A Denison1 shared
Viviana Matta1 shared
V Ashutosh Rao1 shared
Maria J Lopez- Barragan1 shared
Tiara N Brown-Crosen1 shared
Full investigator report
Get the verbatim findings behind Frances Namuswe's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site